Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 1,637 Cr.
- Current Price ₹ 314
- High / Low ₹ 449 / 231
- Stock P/E 49.2
- Book Value ₹ 40.6
- Dividend Yield 0.00 %
- ROCE 17.8 %
- ROE 16.5 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 7.75 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 9.86% over past five years.
- Company has a low return on equity of 12.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|
158 | 140 | 223 | 190 | 219 | 252 | 264 | |
123 | 115 | 175 | 143 | 146 | 170 | 180 | |
Operating Profit | 34 | 25 | 48 | 47 | 73 | 82 | 84 |
OPM % | 22% | 18% | 22% | 25% | 33% | 33% | 32% |
2 | -1 | 2 | 1 | 1 | 4 | 4 | |
Interest | 2 | 2 | 2 | 10 | 10 | 9 | 9 |
Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 36 |
Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 43 |
Tax % | 28% | -1% | 28% | 10% | 26% | 25% | |
15 | 6 | 24 | 6 | 23 | 31 | 32 | |
EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 | 6.11 | 6.80 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 4% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 10% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 13% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 |
Reserves | 111 | 118 | 141 | 147 | 171 | 201 |
13 | 18 | 21 | 99 | 92 | 89 | |
42 | 28 | 32 | 28 | 30 | 33 | |
Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 |
128 | 119 | 119 | 195 | 212 | 223 | |
CWIP | 0 | 0 | 1 | 2 | 1 | 11 |
Investments | 5 | 5 | 0 | 0 | 0 | 1 |
39 | 46 | 80 | 84 | 87 | 99 | |
Total Assets | 173 | 171 | 201 | 281 | 300 | 334 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
31 | 24 | 42 | 44 | 60 | 63 | |
-20 | -28 | -44 | -21 | -35 | -40 | |
-10 | 3 | 1 | -24 | -25 | -24 | |
Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 14 | 16 | 12 | 9 | 15 | 20 |
Inventory Days | 93 | 62 | 38 | 82 | 89 | 100 |
Days Payable | 227 | 177 | 84 | 187 | 193 | 169 |
Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 | -49 |
Working Capital Days | -35 | -19 | -15 | -49 | -37 | -23 |
ROCE % | 8% | 23% | 9% | 17% | 18% |
Documents
Announcements
-
Weblink Letter To Shareholders As Per Regulation 36(1)(B) Of The SEBI (LODR) Regulations, 2015
1d - Dispatched annual report link for FY2024-25; AGM on 05 Sep 2025, 11:30 IST via VC/OAVM.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
18 Aug - Promoter Dr. Somnath Chatterjee acquired 7,800 shares, increasing holding to 5.097% on 18 Aug 2025.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
18 Aug - Promoter Dr. Somnath Chatterjee acquires 7,800 shares, raising holding to 5.097% on 18 Aug 2025.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 18 Aug
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 18 Aug
Concalls
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Dec 2024TranscriptNotesPPT
Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 1,000+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.